Tuesday, August 05, 2025 9:05:57 PM
Jesster, Except you did downplay it. I only provided an informational quote from Andrew’s post, information that the NIH tested DCVax on children with metastatic cancer, that it showed great 5-year results, and that it had amazing survival results. And your reply was that information is over 7 years old.
It’s new information to me. And hands down it is critical for DCVax as it moves forward, ie for cancer patients, RWE, and especially inclusion in a CVPV application if that turns out to be the case.
You subsequently state reasons for why, but none of that “approved in 2 months” was in my post or was it in Andrew’s post, that I was replying to.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176529710
Regardless, in reply to your reasons, I think Andrew’s post about CNPV is relevant. Maybe it was posted years prior and I missed it, but I just learned about it from Andrew posting about it today. We are all trying to keep our fingers on the pulse.
On the CNPV application, it’s possible we submitted an application. Who knows, it could be very possible. I think so because DCVax is an ideal candidate and qualified to do so.
- The UK MAA submission demonstrates validation and credibility
- Advent & Sawston facility, and Flaskworks/Eden in process, demonstrates a capability and a supply chain that can be replicated in the US
- Beartrap posted info from SEC docs about potential manufacturing in the US.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176530900
It’s new information to me. And hands down it is critical for DCVax as it moves forward, ie for cancer patients, RWE, and especially inclusion in a CVPV application if that turns out to be the case.
You subsequently state reasons for why, but none of that “approved in 2 months” was in my post or was it in Andrew’s post, that I was replying to.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176529710
Regardless, in reply to your reasons, I think Andrew’s post about CNPV is relevant. Maybe it was posted years prior and I missed it, but I just learned about it from Andrew posting about it today. We are all trying to keep our fingers on the pulse.
On the CNPV application, it’s possible we submitted an application. Who knows, it could be very possible. I think so because DCVax is an ideal candidate and qualified to do so.
- The UK MAA submission demonstrates validation and credibility
- Advent & Sawston facility, and Flaskworks/Eden in process, demonstrates a capability and a supply chain that can be replicated in the US
- Beartrap posted info from SEC docs about potential manufacturing in the US.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176530900
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
